Priority Area Chronic Lung Diseases, Research Center Borstel, Member of the German Center for Lung Research (DZL), Borstel, Germany.
Department of Rheumatology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China.
Int J Rheum Dis. 2024 Mar;27(3):e15089. doi: 10.1111/1756-185X.15089.
To identify disease-specific serum chemokine profiles and potential anti-inflammatory chemokines in three rheumatic diseases.
The discovery cohort included 18 patients with rheumatoid arthritis (RA), 20 patients with primary Sjögren's syndrome (pSS), 24 patients with systemic lupus erythematosus (SLE) and 28 healthy subjects. Findings from the discovery cohort were validated in two replication cohorts, consisting of 23 patients with SLE matched with 23 healthy subjects and 62 patients with SLE, 16 patients with ANCA-associated vasculitis (AAV), and 32 healthy controls, respectively. Serum levels of chemokines were determined using multiplex assay or ELISA.
In the discovery cohort, serum levels of multiple chemokines were increased in one or more diseases in comparison to healthy subjects, including CCL2, CCL20, CXCL9, CXCL10, and CXCL11 in SLE, CCL2, CCL4, and CXCL11 in pSS, and CCL2, CCL4, and CXCL9 in RA. Notably, serum levels of CCL3 (p = .0003) and CXCL5 (p = .0003) were decreased in SLE. The SLE-specific decrease in CXCL5 serum levels was confirmed in the two replication cohorts, with p = .0034 and p = .0006, respectively. Moreover, a positive correlation between serum levels of CXCL5 and circulating platelet counts (R = .71, p = .00018) in SLE observed in the discovery cohort was confirmed in both replication cohorts (R = .52, p = .011 and R = .49, p = .00005, respectively).
In the present study, we demonstrate that serum levels of CXCL5 are decreased in patients with SLE and positively correlated with circulating platelet count. These findings suggest that platelet-associated CXCL5 is presumably involved in the development of SLE.
鉴定三种风湿性疾病中的疾病特异性血清趋化因子谱和潜在的抗炎趋化因子。
发现队列包括 18 例类风湿关节炎（RA）患者、20 例原发性干燥综合征（pSS）患者、24 例系统性红斑狼疮（SLE）患者和 28 例健康受试者。在两个复制队列中验证了发现队列的结果，分别包括 23 例 SLE 患者与 23 例健康受试者匹配和 62 例 SLE 患者、16 例抗中性粒细胞胞浆抗体相关性血管炎（AAV）患者和 32 例健康对照者。使用多重分析或 ELISA 测定趋化因子的血清水平。
在发现队列中，与健康受试者相比，一种或多种疾病的血清多种趋化因子水平升高，包括 SLE 中的 CCL2、CCL20、CXCL9、CXCL10 和 CXCL11、pSS 中的 CCL2、CCL4 和 CXCL11 以及 RA 中的 CCL2、CCL4 和 CXCL9。值得注意的是，SLE 患者血清 CCL3（p = 0.0003）和 CXCL5（p = 0.0003）水平降低。在两个复制队列中均证实了 SLE 中 CXCL5 血清水平的特异性降低，分别为 p = 0.0034 和 p = 0.0006。此外，在发现队列中观察到的 SLE 患者血清 CXCL5 水平与循环血小板计数之间的正相关（R = 0.71，p = 0.00018）在两个复制队列中均得到证实（R = 0.52，p = 0.011 和 R = 0.49，p = 0.00005）。
本研究表明，SLE 患者血清 CXCL5 水平降低，与循环血小板计数呈正相关。这些发现提示血小板相关的 CXCL5 可能参与了 SLE 的发病机制。
